A phase I/II study of the combination of 5-azacytidine [azacitidine] with valproic acid and all-trans retinoic acid [tretinoin] in patients with high risk myelodysplastic syndrome and acute myelogenous leukaemia.

Trial Profile

A phase I/II study of the combination of 5-azacytidine [azacitidine] with valproic acid and all-trans retinoic acid [tretinoin] in patients with high risk myelodysplastic syndrome and acute myelogenous leukaemia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Jun 2012

At a glance

  • Drugs Azacitidine; Tretinoin; Valproic acid
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Jun 2012 Actual patient number changed from 55 to 34 as reported by ClinicalTrials.gov. (NCT00326170).
    • 14 Jun 2012 Actual patient number changed from 55 to 34 as reported by ClinicalTrials.gov. (NCT00326170).
    • 11 Aug 2009 Actual end date (1 Dec 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top